Zonegran, Zonisamide Newswire
Comprehensive Real-Time News Feed for Zonegran, Zonisamide (generic).
Results 1 - 7 of 7 in Zonegran, Zonisamide (generic)
's stock had its "outperform" rating restated by equities researchers at RBC Capital in a note issued to investors on Monday, StockTargetPrices.com reports. Shares of Concordia Healthcare Corp traded up 2.54% during mid-day trading on Monday, hitting $34.75. Comment?
Myoclonus dystonia is very rare, and Marie Vidailhet and co-researchers stress that their study "is the first controlled therapeutic trial to be conducted in this setting." It involved 23 patients with myoclonus dystonia who were randomly assigned to receive the benzisoxazole derivative zonisamide or placebo for a 6-week dose-escalation period followed by 3 weeks at the highest tolerated dose. Comment?
Concordia Healthcare Corp - Dundee Securities cut their FY2015 EPS estimates for shares of Concordia Healthcare Corp in a research report issued on Monday, according to Zacks Investment Research . Dundee Securities analyst A. Salz now forecasts that the brokerage will post earnings per share of $5.60 for the year, down from their previous estimate of $5.93. Comment?
Concordia Healthcare Corp is set to announce its earnings results after the market closes on Wednesday, March 23rd. Analysts expect the company to announce earnings of $1.42 per share for the quarter. Comment?
Concordia Healthcare Corp - Analysts at Scotiabank decreased their Q1 2016 earnings per share estimates for shares of Concordia Healthcare Corp in a research report issued on Thursday, Zacks Investment Research reports. Scotiabank analyst A. Ridgeway now anticipates that the brokerage will post earnings per share of $1.95 for the quarter, down from their previous forecast of $2.21. Comment?
Shares of Concordia Healthcare Corp have earned an average rating of "Buy" from the seven analysts that are covering the firm, Market Beat Ratings reports . One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. Comment?
This is the largest number of abstracts for eslicarbazepine acetate at a single congress which demonstrates its strong scientific presence in epilepsy. eizure) study programme, a multicentre evaluation of 247 people with partial-onset seizures across eight European countries over six months. Comment?
- « Previous
- Next »
Copyright © 2016 Topix LLC